Summary
1.02 0.06(6.25%)09/13/2024
Bio-Path Holdings Inc (BPTH)
Bio-Path Holdings Inc (BPTH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 4.42 | 5.15 | -26.09 | -49.00 | -81.28 | 155.00 | -91.41 | -99.43 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.02 | |
| Open | 0.99 | |
| High | 1.04 | |
| Low | 0.94 | |
| Volume | 84,922 | |
| Change | 0.04 | |
| Change % | 4.42 | |
| Avg Volume (20 Days) | 107,937 | |
| Volume/Avg Volume (20 Days) Ratio | 0.79 | |
| 52 Week Range | 0.32 - 7.67 | |
| Price vs 52 Week High | -86.70% | |
| Price vs 52 Week Low | 218.75% | |
| Range | 3.08 | |
| Gap Up/Down | 0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3 | |
| EBIDTA | -15,761,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 40.00 | |
| Book Value | 0.7140 | |
| Earnings Per Share | -33.6300 | |
| EPS Estimate Current Quarter | -5.4000 | |
| EPS Estimate Next Quarter | -4.8000 | |
| EPS Estimate Current Year | -18.7100 | |
| EPS Estimate Next Year | -18.4100 | |
| Diluted EPS (TTM) | -33.6300 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -1.0319 | |
| Return on equity (TTM) | -2.2002 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.2133 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | -0.0868 | |
| Shares | ||
| Shares Outstanding | 1,565,310 | |
| Shares Float | 677,845 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.03 | |
| Insider (%) | 0.11 | |
| Institutions (%) | 1.76 | |
09/04 17:48 EST - newsfilecorp.com
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2024. To view the full announcement, including downloadable images, bios, and more, click here.
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2024. To view the full announcement, including downloadable images, bios, and more, click here.
09/03 07:00 EST - globenewswire.com
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET.
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET.
08/15 07:00 EST - globenewswire.com
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2024 and provided an update on recent corporate developments. "The first half of 2024 was marked by considerable corporate and clinical progress across the organization.
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2024 and provided an update on recent corporate developments. "The first half of 2024 was marked by considerable corporate and clinical progress across the organization.
08/08 07:00 EST - globenewswire.com
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and to provide a business overview.
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and to provide a business overview.
07/08 07:00 EST - globenewswire.com
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update on the Company's clinical progress and plans for expansion. “The Bio-Path team continues to work diligently toward advancing our important clinical work and have made meaningful progress in a number of areas critical to each program's success,” said Peter H.
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update on the Company's clinical progress and plans for expansion. “The Bio-Path team continues to work diligently toward advancing our important clinical work and have made meaningful progress in a number of areas critical to each program's success,” said Peter H.
06/14 11:30 EST - investorplace.com
Why Is Bio-Path (BPTH) Stock Up 20% Today?
Bio-Path (NASDAQ: BPTH ) stock is rising higher on Friday alongside data from the oncology-focused company's Phase 2 clinical trial of prexigebersen. Prexigebersen is Bio-Path product candidate for the targeted treatment of acute myeloid leukemia (AML) alongside decitabine and venetoclax.
Why Is Bio-Path (BPTH) Stock Up 20% Today?
Bio-Path (NASDAQ: BPTH ) stock is rising higher on Friday alongside data from the oncology-focused company's Phase 2 clinical trial of prexigebersen. Prexigebersen is Bio-Path product candidate for the targeted treatment of acute myeloid leukemia (AML) alongside decitabine and venetoclax.
06/14 07:00 EST - globenewswire.com
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
06/05 17:46 EST - globenewswire.com
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has closed its previously announced private placement for the issuance and sale of an aggregate of 1,809,955 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 1,809,955 shares of common stock and short-term series B warrants to purchase up to 1,809,955 shares of common stock at a purchase price of $2.21 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $2.00 per share and are exercisable immediately upon issuance. The series A warrants expire five years from the date of issuance and the short-term series B warrants expire twenty-four months from the date of issuance.
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has closed its previously announced private placement for the issuance and sale of an aggregate of 1,809,955 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 1,809,955 shares of common stock and short-term series B warrants to purchase up to 1,809,955 shares of common stock at a purchase price of $2.21 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $2.00 per share and are exercisable immediately upon issuance. The series A warrants expire five years from the date of issuance and the short-term series B warrants expire twenty-four months from the date of issuance.
06/04 16:55 EST - newsfilecorp.com
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024. To view the full announcement, including downloadable images, bios, and more, click here.
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024. To view the full announcement, including downloadable images, bios, and more, click here.
06/03 07:00 EST - globenewswire.com
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
05/24 07:00 EST - globenewswire.com
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)
05/23 17:00 EST - globenewswire.com
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)
05/15 11:04 EST - seekingalpha.com
Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - Chief Executive Officer and Chief Financial Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2024 Earnings Conference Call.
Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - Chief Executive Officer and Chief Financial Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2024 Earnings Conference Call.
05/15 07:00 EST - globenewswire.com
Bio-Path Holdings Reports First Quarter 2024 Financial Results
Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developments.
Bio-Path Holdings Reports First Quarter 2024 Financial Results
Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developments.
05/08 07:00 EST - globenewswire.com
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 15, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview.
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 15, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview.
04/19 12:14 EST - globenewswire.com
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 375,000 shares of its common stock at a purchase price of $3.225 per share and concurrent private placement of unregistered warrants to purchase up to an aggregate of 375,000 shares of common stock. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire five years from the date of issuance.
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 375,000 shares of its common stock at a purchase price of $3.225 per share and concurrent private placement of unregistered warrants to purchase up to an aggregate of 375,000 shares of common stock. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire five years from the date of issuance.
04/19 11:16 EST - zacks.com
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
04/18 13:57 EST - globenewswire.com
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants to purchase up to 375,000 shares of common stock at an exercise price of $3.10 per share. The unregistered warrants to be issued in the private placement will become immediately exercisable upon issuance and will expire five years from the date of issuance. The offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions.
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants to purchase up to 375,000 shares of common stock at an exercise price of $3.10 per share. The unregistered warrants to be issued in the private placement will become immediately exercisable upon issuance and will expire five years from the date of issuance. The offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions.
04/18 10:28 EST - investorplace.com
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Bio-Path (NASDAQ: BPTH ) stock is rising higher on Thursday after the oncology company announced an update on its Phase 1/1b clinical trial of BP1002. This clinical trial is focusing on the use of BP1002 as a treatment for refractory/relapsed acute myeloid leukemia (AML).
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Bio-Path (NASDAQ: BPTH ) stock is rising higher on Thursday after the oncology company announced an update on its Phase 1/1b clinical trial of BP1002. This clinical trial is focusing on the use of BP1002 as a treatment for refractory/relapsed acute myeloid leukemia (AML).